| Document |
Document Title |
|
WO/2022/041615A1 |
The present invention relates to the field of pesticides, and specifically relates to a substituted phenylpyrazoline derivative or a salt thereof as a pesticide, and a composition and use thereof. The compound has the structure of formul...
|
|
WO/2022/040469A1 |
Compounds according to Formula 1 are capable of inhibiting a RAS protein form.
|
|
WO/2022/034616A1 |
Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, pro...
|
|
WO/2022/034529A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses...
|
|
WO/2022/029096A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/029170A1 |
The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the α5 subunit, useful in treating central nervous system diseases and other diseases. In a...
|
|
WO/2022/029068A1 |
The present invention relates to compounds of formula (I), (I), wherein R1, R2, R3, R4 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the c...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/023772A1 |
The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2022/022664A1 |
Disclosed is a type of indolo heptamyl oxime analog crystal as a PARP inhibitor and a method for preparing the same, specifically relating to a crystal of a compound as represented by formula (I) and a method for preparing the same.
|
|
WO/2022/026892A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention ar...
|
|
WO/2021/249913A9 |
The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compound...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/026863A2 |
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managi...
|
|
WO/2022/020247A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein.
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/020522A2 |
The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.
|
|
WO/2022/012593A1 |
A compound represented by general formula (1), a preparation method therefor, and a use of the compound represented by general formula (1), an isomer thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, a hydrate ...
|
|
WO/2022/014724A1 |
A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior inhibitory activity on cancer cell proliferation.
|
|
WO/2022/013312A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2022/015938A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013311A1 |
PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceu...
|
|
WO/2022/008912A1 |
Benzodiazepine derivatives of formula (lb) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C...
|
|
WO/2022/007810A1 |
A tricyclic pyrimidinone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as represented by formula (I), is a completely new Lp-PLA2 inhibitor, and can be used for...
|
|
WO/2022/011204A1 |
The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful ...
|
|
WO/2022/008911A1 |
Benzodiazepine derivatives of formula (Ie) wherein one of R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, -NHR9, benzy...
|
|
WO/2022/005898A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2022/001916A1 |
The present invention relates to a compound of general formula (1a) or general formula (1b) and a preparation method therefor, and use of the compound of general formula (1a) or general formula (1b) and each isomer, each crystal form, ph...
|
|
WO/2022/006220A1 |
Equipotent indolocarbazole-derived analogs of staurosporine identified herein are prepared through C-H borylation chemistry. Functionality resides at C2 and C10 of the indolocarbazole aromatic region. Introducing functionality in this pr...
|
|
WO/2022/006129A1 |
This invention is directed to compositions including IRAK4 inhibitors useful for the treatment of dermatological disorders or conditions characterized by inflammation. This invention is also directed to methods for treating the dermatolo...
|
|
WO/2021/262684A1 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present d...
|
|
WO/2021/261389A1 |
The present invention provides a photoelectric conversion element, an image pickup element, an optical sensor, and a compound that exhibit excellent external quantum efficiency and responsiveness with respect to light having any waveleng...
|
|
WO/2021/255257A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/255258A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/253095A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
|
|
WO/2021/253794A1 |
The invention relates to a maytansine derivative, a synthesis method therefor and a use thereof. The invention constructs an integrative expression vector pSBT11-astC consisting an alanyl enzyme gene astC, realizing heterologous expressi...
|
|
WO/2021/249908A2 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/249522A1 |
A pyridone-containing fused ring derivative inhibitor, a preparation method therefor, and the use thereof. Involved are a compound as represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmace...
|
|
WO/2021/249057A1 |
Provided are an SHP2 inhibitor as represented by formula (I-1), or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, and a pharmaceutical composition thereof and the use of these substances in the treatment and/or preve...
|
|
WO/2021/248764A1 |
The present invention relates to the technical field of medicine synthesis, and specifically relates to a method for preparing a laninamivir octanoate intermediate by means of one-pot synthesis. The method for preparing a laninamivir oct...
|
|
WO/2021/247215A1 |
The present disclosure relates generally to compounds that bind to Ly sopho sphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament...
|
|
WO/2021/205631A9 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on STING. As a result of having performed thoroughgoing studies, the inventors discovered, ...
|
|
WO/2021/244645A1 |
A novel five-membered heteroaromatic imidazole compound and use thereof in preparing a medicament for treating related diseases. Specifically, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/245426A1 |
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic ...
|
|
WO/2021/244608A1 |
Disclosed herein are novel 2,3-dihydro-1H-pyrido[2,3-b][1,4] oxazine or 1,2,3,4-tetrahydropyrido[2,3-b][1,4]oxazepine derivatives used as antagonists of IAPs (Inhibitors Apoptosis Proteins), also known as Smac mimetics. Disclosed herein ...
|
|
WO/2021/242849A1 |
The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful The present disclosure further includes compositions and methods for treating or preventing a bacteria...
|
|
WO/2021/216665A9 |
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound heali...
|
|
WO/2021/238818A1 |
The present invention relates to a macrocyclic JAK inhibitor and the uses thereof. Specifically, the present invention relates to a compound represented by formula I, or a stereoisomer or an optical isomer, a pharmaceutically acceptable ...
|
|
WO/2021/242955A1 |
The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, me...
|
|
WO/2021/239058A1 |
Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activ...
|
